Related Experiment Video
Updated: Mar 20, 2026
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
An intermediate-purity factor VIII concentrate supports platelet adhesion under flow conditions
J Aznar-Salatti1, G Escolar1, C Arnau1
1Dep. Investigación y Desarrollo, Hoechst Ibérica S.A., Barcelona, Spain,Servicio de Hemoterapia y Hemostasia, Hospital ClÃÂnic i Provincial, Barcelona, Spain,Department of Pediatrics, University of Minnesota, Minnesota, USA.
This study demonstrates that von Willebrand factor (vWF) in factor VIII concentrates effectively binds to platelets and enhances platelet adhesion. These findings provide experimental evidence supporting the therapeutic use of vWF concentrates in treating bleeding disorders.
Area of Science:
- Hematology
- Biochemistry
- Medical Science
Background:
- Von Willebrand factor (vWF) is crucial for platelet adhesion and hemostasis.
- Factor VIII concentrates containing vWF are used to treat von Willebrand disease (vWD) types 2 and 3.
- The precise mechanisms of vWF concentrates' effects on hemostasis require further elucidation.
Purpose of the Study:
- To investigate the ability of vWF in an intermediate-purity factor VIII concentrate (Haemate-P) to bind to platelets.
- To assess the capacity of vWF from Haemate-P to support platelet adhesion under flow conditions.
- To provide experimental evidence for the therapeutic benefits of vWF concentrates in hemostasis.
Main Methods:
- Immunoelectron microscopy (IEM) was used to visualize vWF binding to platelets.
- Baumgartner's perfusion method was employed to study platelet adhesion under standardized flow conditions.
- vWF levels were quantified using ristocetin co-factor and vWF-antigen assays.
Main Results:
- IEM confirmed that vWF from Haemate-P binds to platelets.
- Perfusion studies showed significantly increased platelet adhesion with the addition of vWF from Haemate-P compared to vWF-depleted perfusates.
- Cryoprecipitate also demonstrated enhanced platelet adhesion, comparable to the factor VIII concentrate.
Conclusions:
- Fractionated vWF present in Haemate-P effectively binds to platelets.
- The vWF in Haemate-P supports platelet adhesion, confirming its role in hemostasis.
- These findings provide experimental validation for the clinical efficacy of Haemate-P in managing bleeding episodes related to vWD.
